BAX · NYSE
Baxter International Inc.
$26.25 +0.77 (+3.02%)
Company overview
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, along with additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Exchange
- NYSE
- Market cap
- $13.6B
- Employees
- 38,000
- Headquarters
- Deerfield, IL
- Website
- baxter.com
- CEO
- Andrew Hider
- Listed
- October 27, 1981
- P/E
- -12.48
- Dividend yield
- 0.15%
Company financials
- Revenue
- $11.3B
- Gross profit
- $3.4B
- Operating income
- -$300M
- EBITDA
- $744M
- Net income
- -$1.1B
- EPS
- -$2.10
- Total assets
- $19.8B
- Total debt
- $9.7B
- Gross margin
- 30.11%
- Net margin
- -9.70%
- Earnings yield
- -8.01%
Showing FY 2025
BAX
1D
NYSE
O25.11H26.03L24.93C25.48+0.56 (+2.25%)Vol3.92M